Patrick Plewman, the Senior Vice President for Diagnostic Services at Quest Diagnostics, has reported an acquisition of 41 shares of common stock. This transaction took place on October 21, 2026, and was filed with the SEC on October 23, 2026. Such insider purchases often indicate confidence in the company's prospects and can be a positive signal to investors.
Quest Diagnostics, a leader in the medical laboratory services industry, operates under the SIC code for Medical Laboratories. The company is known for providing diagnostic testing services and is headquartered in Secaucus, New Jersey. With a strong presence in the healthcare sector, Quest Diagnostics plays a crucial role in delivering essential medical information to patients and healthcare providers.
According to the SEC filing, Plewman acquired the shares at a price of $235.94 per share. Following this transaction, he now owns a total of 15,334 shares in the company. The filing noted that the shares were acquired through a dividend reinvestment plan, which allows shareholders to reinvest dividends into additional shares of stock.
This acquisition may impact various stakeholders, including other executives, employees, and investors who follow insider trading activities. Such transactions can influence perceptions of the company's stability and growth potential, particularly in a competitive industry where insider confidence can sway market sentiment.
The filing does not specify what happens next regarding Plewman's share ownership or any future transactions.